EXPLOR™ (Exosome engineering for Protein loading
via Optically reversible Protein-Protein interaction)
Photoreceptor CRY2(Cryptochrome2) and CIBN(a truncated version of Cryptochrome Interacting Basic-Helix-Loop-Helix1) protein modules are originally
identified in Arabiodopsis thaliana. CRY2 and CIBN bind under blue light illumination.
EXPLOR™ Technology is a drug loading platform technology, utilizing an aforementioned pair of protein modules.
First, introduce two sets of genes
expressing CRY2-conjugated cargo protein and CIBN-conjugated exosome membrane-associated protein(ex, CD9) into cells. As these cells are incubated
under blue light, the cargo moves into the exosomes via optically induced CRY2-CIBN binding during the process of endogenous biogenesis. After the
secreted exosomes are purified by our isolation procedures, these are injected to patients in order to deliver the therapeutic cargo proteins to target cells.
The platform technology enables us to load large therapeutic proteins into the exosomes thereby we can stably deliver encapsulated cargo proteins to
target cells. This versatile platform technology is to develop innovative exosome-based biomedicines for various diseases with unmet need.
(Publication: Nature Communications, 2016 volume7, Article number: 12277)
Exo-Target® is the exosomes loaded with therapeutic cargo molecule(‘target’ molecule) via various technologies developed by ILIAS Biologics Inc.
ILIAS is developing numerous drugs and simultaneously conducting basic research with Exo-Target® loaded with therapeutic molecules including large proteins.
이메일주소 무단수집을 거부합니다.
본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나 그 밖의 기술적 장치를 이용하여 무단으로 수집되는 것을 거부하며, 이를 위반시 정보통신망법에 의해 형사 처벌됨을 유념하시기 바랍니다.
- 특정물질 수출입